# Reexamining Fat: Exploring Diversity, Plasticity, Development, Functional Implication, and Therapeutic Options

**Authors:** Presley D. Dowker-Key, Praveen Kumar Jadi, Rawon Alfatlawi, Richard J. Giannone, Ahmed Bettaieb

PMC · DOI: 10.3390/ijms27041925 · International Journal of Molecular Sciences · 2026-02-17

## TL;DR

This review explores the complexity of fat tissue, its roles in obesity, and potential therapeutic strategies.

## Contribution

The paper consolidates current knowledge on adipose tissue diversity and evaluates therapeutic approaches for obesity.

## Key findings

- Adipose tissue varies significantly in type, function, and impact on metabolic health.
- Current obesity interventions lack sustained population-level success.
- Emerging therapies show promise but face limitations that need addressing.

## Abstract

Obesity has become so prevalent in many developed countries that it is increasingly perceived as a new norm, despite decades of interventions and drug development. Although research continues to explore novel strategies, no single approach to date has demonstrated sustained success in reducing its population-level dominance. This underscores the need to better evaluate and integrate the growing body of knowledge surrounding obesity’s multifaceted nature. Stamped under one ‘fat’ name, adipose tissue varies by color, location, morphology, composition, and function. This variability suggests a level of complexity that demands deeper investigation. Although the relevance and roles of different adipose types have been extensively discussed throughout the literature, their interdependence, synergy, and collective impact on the body remain to be fully expounded. This review aims to further consolidate and elucidate the available information on the different adipose tissue types and their association with obesity and metabolic health. We also discuss existing and emerging therapeutic strategies, highlighting their respective strengths and limitations.

## Linked entities

- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** COX7A1 (cytochrome c oxidase subunit 7A1) [NCBI Gene 1346] {aka COX7A, COX7AH, COX7AM}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, Cidea (cell death-inducing DNA fragmentation factor, alpha subunit-like effector A) [NCBI Gene 12683], WNT10B (Wnt family member 10B) [NCBI Gene 7480] {aka SHFM6, STHAG8, WNT-12}, REG3A (regenerating family member 3 alpha) [NCBI Gene 5068] {aka HIP, HIP/PAP, INGAP, PAP, PAP-H, PAP1}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, Adipoq (adiponectin, C1Q and collagen domain containing) [NCBI Gene 11450] {aka 30kDa, APN, Acdc, Acrp30, Ad, Adid}, SIM1 (SIM bHLH transcription factor 1) [NCBI Gene 6492] {aka bHLHe14}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CD36 (CD36 molecule (CD36 blood group)) [NCBI Gene 948] {aka BDPLT10, CHDS7, FAT, GP3B, GP4, GPIV}, ZNF423 (zinc finger protein 423) [NCBI Gene 23090] {aka Ebfaz, JBTS19, NPHP14, OAZ, Roaz, ZFP423}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MYF5 (myogenic factor 5) [NCBI Gene 4617] {aka EORVA, bHLHc2}, FGF21 (fibroblast growth factor 21) [NCBI Gene 26291], CITED1 (Cbp/p300 interacting transactivator with ED-rich tail 1) [NCBI Gene 4435] {aka MSG1}, GCGR (glucagon receptor) [NCBI Gene 2642] {aka GGR, GL-R, MVAH}, BAAT (bile acid-CoA:amino acid N-acyltransferase) [NCBI Gene 570] {aka BACAT, BACD1, BAT, FHCA3, HCHO}, TMEM26 (transmembrane protein 26) [NCBI Gene 219623], CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, DLK1 (delta like non-canonical Notch ligand 1) [NCBI Gene 8788] {aka DLK, DLK-1, Delta1, FA1, PREF1, Pref-1}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, DGAT2 (diacylglycerol O-acyltransferase 2) [NCBI Gene 84649] {aka ARAT, GS1999FULL, HMFN1045}, DIO2 (iodothyronine deiodinase 2) [NCBI Gene 1734] {aka 5DII, D2, DIOII, SELENOY, SelY, TXDI2}, ATXN1 (ataxin 1) [NCBI Gene 6310] {aka ATX1, D6S504E, SCA1}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, HTR2C (5-hydroxytryptamine receptor 2C) [NCBI Gene 3358] {aka 5-HT1C, 5-HT2C, 5-HTR2C, 5HTR2C, HTR1C}, CIT (citron rho-interacting serine/threonine kinase) [NCBI Gene 11113] {aka CITK, CRIK, MCPH17, STK21}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, ATF2 (activating transcription factor 2) [NCBI Gene 1386] {aka CRE-BP1, CREB-2, CREB2, HB16, TREB7}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, Ucp1 (uncoupling protein 1 (mitochondrial, proton carrier)) [NCBI Gene 22227] {aka Slc25a7, Ucp}, IGFBP2 (insulin like growth factor binding protein 2) [NCBI Gene 3485] {aka IBP2, IGF-BP53}, RARRES2 (retinoic acid receptor responder 2) [NCBI Gene 5919] {aka HP10433, TIG2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, MAT1A (methionine adenosyltransferase 1A) [NCBI Gene 4143] {aka MAT, MATA1, SAMS, SAMS1}, NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, PRDM16 (PR/SET domain 16) [NCBI Gene 63976] {aka CMD1LL, KMT8F, LVNC8, MEL1, PFM13}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, CIDEA (cell death inducing DFFA like effector a) [NCBI Gene 1149] {aka CIDE-A}, GIP (gastric inhibitory polypeptide) [NCBI Gene 2695], CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, SDC1 (syndecan 1) [NCBI Gene 6382] {aka CD138, SDC, SYND1, syndecan}, BMP7 (bone morphogenetic protein 7) [NCBI Gene 655] {aka OP-1}
- **Diseases:** weight loss (MESH:D015431), DIT (MESH:D000092582), bone adiposity (MESH:D001847), hepatic insulin resistance (MESH:D007333), disuse osteoporosis (MESH:D020966), overnutrition (MESH:D044343), osteoporotic (MESH:D058866), cardiovascular disease (MESH:D002318), neurotoxicity (MESH:D020258), non-alcoholic fatty liver disease (MESH:D065626), overactive bladders (MESH:D053201), leptin resistance (OMIM:614962), infection (MESH:D007239), addictions (MESH:D019966), AD (MESH:D000544), cancer (MESH:D009369), COVID-19 (MESH:D000086382), pulmonary disorders (MESH:D008171), valvular abnormalities (MESH:D006349), immune disorders (MESH:D007154), diabetes (MESH:D003920), venous thromboembolism (MESH:D054556), undernutrition (MESH:D044342), death (MESH:D003643), dyslipidemia (MESH:D050171), fracture (MESH:D050723), atherosclerotic lesion (MESH:D050197), inflammation (MESH:D007249), injury to (MESH:D014947), hypothermia (MESH:D007035), cardiometabolic disease (MESH:D024821), rheumatoid arthritis (MESH:D001172), fibrosis (MESH:D005355), lethargic (MESH:D004674), hyper (MESH:D007589), visceral adiposity (MESH:D007418), vomiting (MESH:D014839), iron deficiency (MESH:D000090463), pulmonary hypertension (MESH:D006976), sepsis (MESH:D018805), Congenital generalized lipodystrophy (MESH:D052497), lipodystrophy (MESH:D008060), metabolic (MESH:D008659), skeletal fragility (MESH:D005600), autosomal recessive disorder (MESH:D030342), atherosclerotic plaque (MESH:D058226), neurological disturbances (MESH:D009461), clinical (MESH:D000075902), kidney cancer (MESH:D007680), hyperplasia (MESH:D006965), hyperthermia (MESH:D005334), hyperphagia (MESH:D006963), hepatic injury (MESH:D056486), constipation (MESH:D003248), cardiac dysfunction (MESH:D006331), anorexia nervosa (MESH:D000856), diarrhea (MESH:D003967), insulin-deficient diabetic (MESH:D003922), weight gain (MESH:D015430), loss of bone mineral density (MESH:D001851)
- **Chemicals:** Phosphatidic acid (MESH:D010712), bisphenol-A-diglycidyl ether (MESH:C019273), 18F-FDG (MESH:D019788), TAG (MESH:D014280), ester (MESH:D004952), fatty acid (MESH:D005227), polymer (MESH:D011108), carbohydrate (MESH:D002241), PC (MESH:D010713), 9-PAHSA (MESH:C000631240), creatine (MESH:D003401), PS (MESH:D010718), PVA (MESH:D011142), ALA (MESH:D008063), FAU (MESH:C054103), prostaglandin (MESH:D011453), TG (MESH:D013866), sugar (MESH:D000073893), Hydroxy-alpha-sanshool (MESH:C000598329), rosiglitazone (MESH:D000077154), glycerol (MESH:D005990), oxygen (MESH:D010100), CL-316243 (MESH:C076126), 18F-FTHA (-), palmitoleate (MESH:C008757), cholesterol (MESH:D002784), magnesium (MESH:D008274), 11C-acetate (MESH:C438206), flavonoids (MESH:D005419), fenfluramine (MESH:D005277), glucose (MESH:D005947), FA (MESH:D005492), calcium (MESH:D002118), cAMP (MESH:D000242), monoacylglycerol (MESH:D050178), blood glucose (MESH:D001786), Resveratrol (MESH:D000077185), poly(lactide-co-glycolide) (MESH:D011098), NAD)+ (MESH:D009243), PLGA (MESH:D000077182), dinitrophenol (MESH:D004140), stearyl-octa arginine (MESH:C487882), Norepinephrine (MESH:D009638), H+ (MESH:D006859), mirabegron (MESH:C520025), guanosine diphosphate (MESH:D006153), alkaloids (MESH:D000470), DAG (MESH:D004075), tryptophan (MESH:D014364), Amphetamine (MESH:D000661), alcohol (MESH:D000438), FO (MESH:D005395), lipid (MESH:D008055), FFA (MESH:D005230), alpha-tocopherol acetate (MESH:D024502), streptozotocin (MESH:D013311), OH (MESH:C031356), Endocannabinoids (MESH:D063388), polyphenol (MESH:D059808), adenosine triphosphate (MESH:D000255)
- **Species:** Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606], Marmota marmota (European marmot, species) [taxon 9993], Staphylococcus aureus (species) [taxon 1280], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], gut metagenome (species) [taxon 749906], Zanthoxylum bungeanum (Sichuan-pepper, species) [taxon 328401]
- **Cell lines:** 3T3-L1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0123), C3H10T1/2 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0190)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940824/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940824/full.md

## References

584 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940824/full.md

---
Source: https://tomesphere.com/paper/PMC12940824